Abstract
Dapagliflozin is a highly selective SGLT2 inhibitor. Following its administration, glucose reabsorption in the proximal tubule is decreased.
In individuals with diabetes, dapagliflozin reduces glycated haemoglobin by 0.5-0.8% in comparison with placebo, with its effect being independent on the presence of insulin. Dapagliflozin reduces body weight, waist circumference, and the volume of both visceral and subcutaneous fat.
Dapagliflozin slightly decreases systolic blood pressure. In November 2012, dapagliflozin was registered for the treatment of type 2 diabetes patients under the name Forxiga.
The basic therapeutic dose is 10 mg of dapagliflozin. It is indicated as monotherapy or combination therapy, including a combination with insulin.
Genital fungal infections are the most common adverse effect.